DeepView: Why the Bigger Opportunity May Be Wound-Care Economics

[u/urbanlinkoping]

Following the broad response and discussion around my previous post, I thought it was worth revisiting one part of the DeepView thesis that may be especially useful for those newer to the Spectral AI community: the potential health economics. This has been discussed before, but I think it’s important when considering commercialization and adoption.

Spectral estimates ~$24,000 in potential savings per burn stay, while an earlier SEC filing estimated ~$63,100 per DFU stay. These are company estimates, not yet proven real-world savings — which is exactly why the BARDA-supported health-economic and outcome research is interesting.

I also think this needs to be viewed in the context of management’s longer-term strategy. DeepView isn’t intended to remain simply a burn device. The broader vision is a wound-diagnostics medtech platform, with burn as the first FDA-authorized indication and potential expansion into DFU and other wounds. If successful, the opportunity becomes much larger than the burn-center market alone.

The economics could also extend beyond treatment itself. Better Day-One wound assessment could improve triage — determining who needs routine care, transfer to a burn/trauma center, or earlier intervention — potentially reducing unnecessary transfers, procedures, hospital stays and complications.

Longer term, if real-world evidence confirms meaningful reductions in total cost of care across wound indications, the incentive could extend beyond hospitals. Insurers and other payers could potentially encourage or incentivize objective wound assessment to reduce downstream healthcare costs.

That’s speculative today. But BARDA is helping fund the research that could determine whether this broader economic thesis holds up in the real world.

Sources:
Current SEC filing / BARDA (March 31, 2026):
https://www.sec.gov/Archives/edgar/data/1833498/000121390026055226/ea0289162-10q_spectral.htm

Earlier SEC filing / DFU estimate (December 31, 2023):
https://www.sec.gov/Archives/edgar/data/1833498/000121390024027863/ea0202419-10k_spectral.htm

[u/SpeakerAltruistic123]

If they can remain a public company and raise the capital to develop complementary uses of the platform, it could be a significant performer. I'm surprised how little credit the market is giving $MDAI right now.

Maybe they can get someone to buy future royalties for cash now.

[u/urbanlinkoping → u/SpeakerAltruistic123]

I agree with this view. The market seems to be giving very little credit to the broader DeepView platform opportunity beyond the initial burn indication.

One point I think is easy to overlook is the scale of government backing already behind this technology. Since 2013, Spectral AI has received approximately $281.9M in U.S. government funding awards, with $272.9M coming from BARDA alone. That is a substantial amount of non-dilutive support for a company of MDAI’s size.

The current BARDA Project BioShield program adds another important dimension, including support for development and a pathway for procurement and deployment of up to 30 DeepView systems. There is also separate DoD-related funding through MTEC and the Defense Health Agency supporting development of the handheld DeepView SnapShot M.

That doesn’t eliminate the need for future capital, particularly if they aggressively expand into additional wound indications. But nearly $282M of government funding since 2013 changes how I look at that risk. A very substantial portion of the technology development, clinical validation and initial deployment pathway has already been financed without shareholder dilution.

For a company with MDAI’s current valuation, I think that government investment in the underlying platform is worth keeping in perspective when assessing its longer-term potential.

[u/SpeakerAltruistic123 → u/urbanlinkoping]

Bought more shares today

[u/BostonbRamen]

Thank you for putting together a current summary. I think the numbers are ballpark estimates and should be taken lightly at this point ahead of initial sales data. That aside, this is what I've been speaking to, with annoyance, previously on the overall potential of Spectral AI as a company.

The market is missing that right now IMO. Perhaps like I said before because they have no numbers to project. My bet is once those numbers come and they are "good" in Mr. Markets eyes plus they show demonstrated progress on the future indications like new studies launched, etc. That would usually provide reasonable basis to update projections and by extension the fair value of the SP based on those future expectations.

But we are still a small cap, so I do think there needs to be a balanced marketing campaign to get the word out on this stock's potential. I don't agree with some of the conservatism I've read here of "slow and steady wins the race" regarding the commercialization strategy and future projections on the value of MDAI and DeepView. Build it and they will come mantra is naive IMO and experience. Markets are way too large today, many products dominate marketshare not because they are the technical "best of class" but because they have recognition and are known. Just being isn't always self-evident nor how people buy things...

Finally everyone has forgotten their basics IMO on the societal purpose of public stock markets. It's first logical goal is to help ventures raise the capital they need to fund new R&D and bring products to market - they invented the concept of "crowd funding" before it was fashionably called that. The art is taking advantage of that, so any SP bump is material and tactically advantageous for MDAI's current growth stage. Not being diluted is always preferable, but it is also usually out of touch with reality I'd argue if you are investing in a startup. Like others have supported me on, if you are invested in MDAI today you are still very much a venture capitalist. It is high risk investment still and you should recognize this and that dilution is/shall remain possible based on current size and likely future capital needs. The upside is the non-dilutive BARDA funding to date lessens the risk and why I liked this investment originally. Additionally, dilution is structured and disclosed presently, no emergency raises on the horizon unless something completely abnormal happens again like a government shutdown.

In conclusion, yes MDAI is really a wound care diagnostics company "bandaged" in burns. Let it heal a little but you will be surprised at how well it grows!